Your insurer denied a treatment as experimental or investigational — what that determination actually means
When an insurer calls a treatment "experimental" or "investigational," they are applying their own internal criteria — not necessarily the same criteria your doctor or the medical literature would apply. This is one of the most frequently challenged denial categories, and one of the most frequently reversed on external review. But the challenge requires specific documentation.
The insurer's definition and the clinical definition may differ
Insurance plans define "experimental" and "investigational" in their plan documents. These definitions typically look for one or more of the following:
- The treatment lacks FDA approval for the specific indication
- The treatment is not accepted as standard of care by recognized medical bodies
- The evidence for the treatment does not meet the plan's evidence standards (often requiring randomized controlled trials)
- The treatment is the subject of active clinical trials
The problem is that "accepted by recognized medical bodies" and "meets evidence standards" are judgments the insurer makes using their own criteria — often criteria that are more restrictive than what practicing specialists in the field would apply.
Accepting the "experimental" characterization and arguing only around the edges. The right first move is to identify exactly what criteria the insurer applied, then challenge whether your treatment actually falls under those criteria — using published medical literature, specialty society guidelines, and your doctor's clinical documentation.
Get the specific criteria in writing
Before writing your appeal, request the following from the insurer:
- The specific definition of "experimental" or "investigational" in your plan document
- The specific evidence criteria the insurer applied to determine that your treatment falls under that definition
- The name and credentials of the reviewer who made the determination
- Any clinical guidelines or technology assessment reports the insurer relied on
Insurers sometimes rely on outdated technology assessments or criteria that have not kept pace with current clinical practice. Identifying those specifically is the foundation for a strong appeal.
Counter the criteria, not just the label
A strong appeal for an experimental treatment denial does one or more of the following:
- Cites published peer-reviewed literature showing the treatment is effective and accepted in clinical practice
- Cites specialty society guidelines (ACOG, ACR, AAOS, etc.) endorsing the treatment for your indication
- Shows that the treatment has FDA approval for a related indication and is used off-label with documented clinical support
- Identifies that the insurer's criteria are outdated relative to current evidence
- Includes your treating physician's clinical documentation explaining why the treatment is the recognized standard of care for your condition
"Please provide me with: (1) the specific definition of 'experimental' or 'investigational' in my plan document; (2) the specific criteria applied to determine that [treatment] falls under that definition; (3) any clinical guidelines or technology assessments the insurer relied on; and (4) the credentials of the reviewer who made this determination."
Get this information before drafting your appeal. The appeal is most powerful when it addresses the specific criteria — not just the general question of whether the treatment is established.
External reviewers apply different standards than insurers
Independent external review organizations are required to apply generally accepted standards of medical practice — not the insurer's proprietary criteria. For experimental treatment denials specifically, this distinction matters: external reviewers frequently find that treatments the insurer characterized as experimental are, in fact, consistent with accepted medical practice for the treating specialty.
External review is available after internal appeals are exhausted. It is often the strongest option for experimental treatment denials because the reviewer is independent of the insurer and not bound by the insurer's criteria.
Free denial pattern classification identifies a likely pattern, the missing fact to check, and the next question to ask. No account required.
Free denial classification — 30 secondsFrequently asked questions
Insurers apply their own criteria for what counts as experimental — these are based on their plan documents and internal coverage policies, not necessarily on what specialists in your doctor's field consider standard practice. The gap between what your treating physician considers established and what the insurer's criteria require is common, especially for newer treatments, off-label uses, or treatments for rare conditions. Your appeal needs to address the insurer's specific criteria directly.
Not necessarily. FDA approval means the agency has reviewed the treatment for safety and efficacy for a specific indication. Insurance plans may still consider a treatment experimental if it's being used for a different indication than what it was approved for (off-label use), or if the plan's evidence criteria require additional clinical evidence beyond FDA approval. However, FDA approval is relevant evidence for your appeal — particularly when combined with specialty society guidelines endorsing the use.
External review has a higher reversal rate for experimental treatment denials than for other denial types, in part because external reviewers apply generally accepted clinical standards rather than insurer-specific criteria. Independent studies have shown reversal rates of 40–50% for experimental/investigational denials in external review. If your internal appeal is denied, external review is typically worth pursuing.
Federal law (the ACA) requires most health plans to cover routine patient costs for members participating in approved clinical trials, even if the trial treatment itself is not covered. If your treatment is only available through a clinical trial, ask your insurer whether your plan covers routine clinical costs. This is a separate coverage question from whether the treatment itself is covered as a standalone service.
Three pillars · classification, coordination, record-building · how coordination works → · administrative record-building, not legal action.